Platform

A Totally New Approach To Infectious Disease

Destiny’s XF drug series represents a totally new antimicrobial drug platform. With a novel structure, unique mechanism of action and a remote potential for bacterial resistance emergence.

Applications are being pursued which address the prevention and treatment of multidrug-resistant bacteria, as exemplified by the lead drug asset XF-73 (exeporfinium chloride) for the prevention of post-surgical Staphylococcal infections where the drug’s rapid action and low potential for resistance emergence offer the greatest benefits.

Additional R&D programmes with other drugs from the platform have generated data based on a number of infection models which show promise to extend the preventative and therapeutic product pipeline of Destiny Pharma.